...comprising ATB200 and the pharmacological chaperone AT2221, in Phase I/II testing to treat Pompe’s disease. Oxyrane U.K. Ltd....

...a rhGAA, and the pharmacological chaperone AT2221, in Phase I/II testing to treat Pompe’s disease. Oxyrane U.K. Ltd....

...uniQure N.V. (NASDAQ:QURE) hired Charles Richard as SVP of neuroscience R&D. Richard was CMO at Oxyrane U.K. Ltd....

...heart and thigh muscle of glycogen better than unmodified GAA. Next steps carried out by Oxyrane U.K. Ltd....
...Nat. Biotechnol.; published online Nov. 18, 2012; doi:10.1038/nbt.2427 Contact: Wouter Vervecken, Oxyrane U.K. Ltd., Manchester, U.K. e-mail: wvervecken@oxyrane.com...

...from Sanofi . 1,2 BioMarin has moved its therapy into a Phase I/II trial, whereas Oxyrane...
...to long infusion times and adverse reactions, including fever, tachycardia, cyanosis and hypotension. 4 Thus, Oxyrane...
...Biotechnol. ; published online Nov. 18, 2012; doi:10.1038/nbt.2427 Contact: Wouter Vervecken, Oxyrane U.K. Ltd., Manchester, U.K. e-mail: wvervecken@oxyrane.com...

...Phase III trials. Some of those reactions were severe, including fever, tachycardia, cyanosis and hypotension. Oxyrane...
...enzyme would have a potential value advantage over Myozyme," said Sander Slootweg, a director at Oxyrane...
...investor New Science Ventures in Oxyrane's $26.5 million series D round. To increase cellular uptake, Oxyrane...

...round. New investors Forbion Capital Partners and Morningside Group joined existing investor New Science Ventures. Oxyrane...
...for greater efficacy at lower product doses. Forbion's Sander Slootweg and Morningside's Gerald Chan joined Oxyrane's...